1. US FDA. Best Practices in Developing Proprietary Names for Human Nonprescription Drug Products. Drug Saf. USA; 2020. http://www.fda.gov/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/default.htmand/or.
2. Health Canada. Guidance document for industry-Review of drug brand names. Ottawa; 2014. https://www.canada.ca/content/dam/hc-sc/migration/hc-sc/dhp-mps/alt_formats/pdf/pubs/medeff/guide/2014-review-examen_drug-medicament_names-marques/2014-review-examen_drug-medicament_names-marques-eng.pdf.
3. MHRA. Mhra Guideline for the Naming of Medicinal Products and Braille Requirements for Name on Label. London; 2019. https://www.canada.ca/content/dam/hc-sc/migration/hc-sc/dhp-mps/alt_formats/pdf/pubs/medeff/guide/2014-review-examen_drug-medicament_names-marques/2014-review-examen_drug-medicament_names-marques-eng.pdf
4. EMA, CHMP. Guideline on the acceptability of names for human medicinal products processed through the centralised procedure. 2014.
5. Centre for Patient Safety Solutions. Look-Alike, Sound-Alike Medication Names. WHO Press. World Heal. Organ. WHO Press, World Health Organization; 2007. https://linkinghub.elsevier.com/retrieve/pii/S1553725007330493